AAV2-based VEGF/PDGF hybrid gene therapy (Sanofi)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAAV2-based VEGF/PDGF hybrid gene therapy (Sanofi)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 1 antagonists
TargetsVascular endothelial growth factor receptor 1Platelet-derived growth factor receptor
Therapy Area/IndicationsWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenzyme Corp
Active IndicationsN/A
Inactive IndicationsWet age-related macular degeneration

Other Information

ATC CodeN/A
Related LinksN/A